JP2019099571A5 - - Google Patents

Download PDF

Info

Publication number
JP2019099571A5
JP2019099571A5 JP2018223465A JP2018223465A JP2019099571A5 JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5 JP 2018223465 A JP2018223465 A JP 2018223465A JP 2018223465 A JP2018223465 A JP 2018223465A JP 2019099571 A5 JP2019099571 A5 JP 2019099571A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018223465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019099571A (ja
JP7461104B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019099571A publication Critical patent/JP2019099571A/ja
Publication of JP2019099571A5 publication Critical patent/JP2019099571A5/ja
Priority to JP2024045935A priority Critical patent/JP7767492B2/ja
Application granted granted Critical
Publication of JP7461104B2 publication Critical patent/JP7461104B2/ja
Priority to JP2025182210A priority patent/JP2026016628A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018223465A 2017-11-29 2018-11-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 Active JP7461104B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024045935A JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A JP2026016628A (ja) 2017-11-29 2025-10-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017228661 2017-11-29
JP2017228661 2017-11-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024045935A Division JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP2019099571A JP2019099571A (ja) 2019-06-24
JP2019099571A5 true JP2019099571A5 (enExample) 2022-01-06
JP7461104B2 JP7461104B2 (ja) 2024-04-03

Family

ID=66975925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018223465A Active JP7461104B2 (ja) 2017-11-29 2018-11-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024045935A Active JP7767492B2 (ja) 2017-11-29 2024-03-22 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2025182210A Pending JP2026016628A (ja) 2017-11-29 2025-10-29 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Country Status (1)

Country Link
JP (3) JP7461104B2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110618208A (zh) * 2019-09-10 2019-12-27 威海迪素制药有限公司 一种(s)-(+)-3-羟基四氢呋喃对映异构体含量检测方法
PE20231066A1 (es) 2020-02-07 2023-07-17 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1
MX2023000943A (es) * 2020-07-20 2023-02-22 Eccogene Shanghai Co Ltd Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.
CN116615430A (zh) * 2020-09-07 2023-08-18 加舒布鲁姆生物公司 杂环glp-1激动剂
JP7858636B2 (ja) * 2020-09-10 2026-05-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
WO2023016546A1 (en) * 2021-08-12 2023-02-16 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
FI4408840T3 (fi) 2021-09-27 2025-11-04 Terns Pharmaceuticals Inc Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
EP4522129A1 (en) * 2022-05-11 2025-03-19 Eli Lilly And Co. Glp1 pharmaceutical compositions
EP4522131A1 (en) * 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions
JP2026500505A (ja) * 2022-12-13 2026-01-07 イーライ リリー アンド カンパニー 2型糖尿病(t2d)、肥満、又は少なくとも1つの体重関連併存症を伴う過体重を有する対象を治療するためのオルフォルグリプロンの投与レジメン
EP4634156A1 (en) * 2022-12-15 2025-10-22 Sironax Ltd Sarm1 modulators, preparations, and uses thereof
CN120659776A (zh) 2022-12-19 2025-09-16 伊莱利利公司 Glp1 ra及其中间体的制备方法
AU2024210933A1 (en) * 2023-01-17 2025-08-07 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
TWI912812B (zh) * 2023-06-29 2026-01-21 大陸商韋恩生物科技有限公司 一種glp-1受體激動劑及其製備方法和用途
KR20260030832A (ko) * 2023-06-30 2026-03-06 치아타이 티안큉 파마수티컬 그룹 주식회사 다축합환 구조를 포함하는 화합물
AU2024317579A1 (en) * 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025097835A1 (zh) 2023-11-10 2025-05-15 重庆医药工业研究院有限责任公司 一种glp-1r激动剂化合物及其应用
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
CN120136870A (zh) * 2023-12-05 2025-06-13 信达生物科技有限公司 靶向glp-1受体的化合物以及其用途
WO2025124357A1 (zh) * 2023-12-14 2025-06-19 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
WO2025208111A1 (en) 2024-03-29 2025-10-02 Biomea Fusion, Inc. Heterocyclic glp-1r agonists
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026032183A1 (en) * 2024-08-05 2026-02-12 Rongchang Pharmaceuticals, Ltd. Nitrogen-containing fused ring compound, pharmaceutical composition and use thereof
CN121627686A (zh) * 2024-09-09 2026-03-10 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂
WO2026096330A1 (en) * 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101050700B1 (ko) 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
CA2757084C (en) 2009-03-30 2017-08-29 Transtech Pharma, Inc. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2014122067A1 (en) 2013-02-06 2014-08-14 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
EP2993174A1 (en) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Similar Documents

Publication Publication Date Title
JP2021502066A5 (enExample)
JP2019030304A5 (enExample)
JP2020042034A5 (enExample)
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2021185136A5 (enExample)
JP2021169491A5 (enExample)
JP2021518389A5 (enExample)
JP2019031552A5 (enExample)
JP2018154848A5 (enExample)
JP2020534795A5 (enExample)
JP2020007340A5 (enExample)
JP2020040981A5 (enExample)
JP2021503478A5 (enExample)
JP2019068846A5 (enExample)
JP2021500894A5 (enExample)
JP2021038271A5 (enExample)
JP2017214405A5 (enExample)
JP2016196495A5 (enExample)
JPWO2020148954A5 (enExample)
JP2018135352A5 (enExample)
JP2021524864A5 (enExample)
JP2021502339A5 (enExample)
JP2018111825A5 (enExample)
JP2016028081A5 (enExample)